Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclooxygenase-2 expression in pediatric sarcomas.

David S Dickens1, Rafal Kozielski, Javed Khan

  • 1Department of Pediatrics, Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA. dicq3z@chmc.org

Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
|May 25, 2002
PubMed
Summary

Pediatric sarcomas like rhabdomyosarcoma, osteosarcoma, and Ewing sarcoma frequently overexpress cyclooxygenase-2 (COX-2). This suggests that targeting COX-2 with inhibitors may offer a less toxic therapeutic approach for these challenging childhood cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers.

Cell reports. Medicine·2026
Same author

Phyto-Nanotherapeutics for Alzheimer's Disease: Current Progress and Future Perspectives.

Central nervous system agents in medicinal chemistry·2026
Same author

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

British journal of cancer·2026
Same author

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

JCO precision oncology·2026
Same author

An insight into the molecular identity and distribution of <i>Microhyla taraiensis</i> (Anura, Microhylidae) in Khyber Pakhtunkhwa, Pakistan.

ZooKeys·2026
Same author

Enhancing Compliance: Tailored Training on IATA Regulations for Shipping Infectious Substances and Biological Specimens for Targeted Cohorts in Pakistan.

Applied biosafety : journal of the American Biological Safety Association·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Pediatric Cancer Research

Background:

  • Current therapies for metastatic pediatric sarcomas have limited efficacy and significant side effects.
  • Cyclooxygenase-2 (COX-2) is overexpressed in various adult solid tumors, with COX-2 inhibitors demonstrating antiproliferative effects.

Purpose of the Study:

  • To investigate the expression of cyclooxygenase-2 (COX-2) in pediatric sarcoma samples.
  • To assess the potential of COX-2 as a therapeutic target in pediatric sarcomas.

Main Methods:

  • Immunohistochemical analysis of COX-2 expression in pediatric sarcoma tissues.
  • cDNA microarray analysis to evaluate COX-2 gene expression in rhabdomyosarcoma (RMS), osteosarcoma (OS), and Ewing sarcoma (EWS).

Main Results:

Related Experiment Videos

  • COX-2 expression was detected in a high percentage of pediatric sarcoma samples (82.8% by immunohistochemistry, 88.1% by microarray).
  • A trend towards increased COX-2 expression was observed in metastatic RMS and OS, but did not reach statistical significance.
  • No significant correlation was found between COX-2 immunoreactivity and clinicopathologic features like age, gender, or histology.

Conclusions:

  • The majority of pediatric sarcomas (RMS, OS, EWS) express cyclooxygenase-2 (COX-2).
  • These findings support further investigation into the efficacy of COX-2 inhibitors as a novel therapeutic strategy for pediatric sarcomas.